With all the news about EpiPen recently, the pharmaceutical industry feels more like the needles-under-cuticles industry lately. Nuvo Pharmaceuticals (NRI.TO) seems to be bucking the trend with its products. In the middle of the EpiPen controversy, this stock is able to break out to new 52-week highs and also above a serious resistance level for the stock. I like the breakout here after creating higher lows and now popping through to new highs.
There is a slight level of resistance with one weekly closing high at $8.02 and one at $8.45 from a few years back.
I like the rising MACD and the strong SCTR reading. One pause is the low volume, but I think the stock is worth watching as long as your position size is not too large.
Greg Schnell, CMT, MFTA.
About the author:Greg Schnell, CMT, is a Senior Technical Analyst at StockCharts.com specializing in intermarket and commodities analysis. Based in Calgary, he is a board member of the Canadian Society of Technical Analysts (CSTA) and the chairman of the CSTA Calgary chapter. He is an active member of both the Market Technicians Association (MTA) and the International Federation of Technical Analysts (IFTA).
Greg is also the co-author of Stock Charts for Dummies (Wiley, 2018).
Greg joined StockCharts.com in 2012 and has be instrumental in helping launch a variety of new blogs and other commentary platforms. Presently, Greg contributes market analysis commentary to The Canadian Technician, Commodities Countdown and Don't Ignore This Chart blogs.